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Chronic graft-versus-host disease (CGVHD) is one of the most significant complications 
of long-term survivors after allogeneic hematopoietic stem cell transplantation 
(allo-HSCT). CGVHD may have protean manifestations and can pose unique diagnostic 
and therapeutic challenges. New recommendations that emphasize the importance of 
qualitative differences, as opposed to time of onset after HSCT, are now being used to 
standardize the diagnosis and clinical assessment of CGVHD, but they require validation. 
During the past 3 decades, experimental studies and clinical observations have elucidated 
the mechanisms of acute GVHD, but its biology is much less well-understood. 
Experimental studies have generated at least 4 theories to explain the pathophysiology 
of CGVHD: (1) thymic damage and the defective negative selection of T cells, (2) regu-
latory T cell deficiencies, (3) auto-antibody production by aberrant B cells, and (4) the 
formation of profibrotic lesions. Mouse models have provided important insights into 
the pathophysiology of CGVHD, and these have helped improve clinical outcomes follow-
ing allo-HSCT, but no animal model fully replicates all of the features of CGVHD in humans. 
In this article, recent clinical changes, the pathogenesis of CGHVD, the cellular and cyto-
kine networks implicated in its pathogenesis, and the animal models used to devise strat-
egies to prevent and treat CGVHD are reviewed.
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INTRODUCTION
  Chronic graft-versus-host disease (CGVHD) remains a ma-
jor cause of late morbidity and mortality after allogeneic 
hematopoietic stem cell transplantation (allo-HSCT) [1]. The 
incidence of CGVHD following allo-HSCT ranges from 25% 
to 80%; the occurrence of CGVHD is associated with immune 
dysfunction and thus, a risk of infection and reduced quality 
of life [2], even though CGVHD is also associated with a 
lower relapse rate, presumably because of graft-versus-leuke-
mia effects [3]. Over the past 10 years, CGVHD has emerged 
as the most troublesome complication of allo-HSCT. Impro-
vements in human histocompatibility antigen (HLA) typing 
for unrelated transplantation, the adoption of new acute 
GVHD prophylaxis measures, reductions in conditioning reg-
imen intensity, the introduction of new antimicrobial agents, 
and advances in supportive care have all helped to mitigate 
early morbidity and mortality in patients after allo-HSCT. 
However, because more and more patients survive the early 
post-transplant period, the number of individuals at risk 
for CGVHD continues to grow. This trend, in conjunction 
with the escalating use of mobilized peripheral blood cells 
as a preferred stem cell source, has led to a significant increase 
in the number of transplant survivors living with, and in 
some cases dying from, CGVHD [3-8]. Unfortunately, the 
treatment of established CGVHD remains unsatisfactory. 
Corticosteroids are the mainstay of therapy, but are often 
not fully effective, and their long-term use leads to multiple 
complications [1, 9]. Other agents such as calcineurin in-
hibitors, sirolimus, mycophenolate mofetil, thalidomide, 
pentostatin, mesenchymal stem cells, and extracorporeal 
photopheresis have all produced responses in phase 2 studies, 
but no agent has yet demonstrated superiority to steroids 
alone in a randomized clinical trial [10-19]. 
During the past 3 decades, experimental studies and clin-
ical observations have elucidated the pathophysiology of 
acute GVHD, but the biology of CGVHD has not been deter-
mined. In particular, defining the pathophysiology of CGVHD 
has been complicated by the absence of animal models that 
accurately recapitulate the disease or its clinical setting; this 
is in contrast to acute GVHD, in which murine models of Korean J Hematol 2011;46:80-7.
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major histocompatibility (MHC) mismatched HSCT provide 
a reasonably comprehensive picture of its pathophysiology 
as a clinical disease [20]. The purpose of this review is to 
briefly describe the pathophysiology of CGVHD, on the basis 
of phenotype and immunologic mechanisms that encompass 
the majority of murine CGVHD models described to date. 
Their relevance to clinical CGVHD is also discussed.
DEFINITION
CGVHD was initially defined as a GVHD syndrome that 
presents more than 100 days post-transplant, either as an 
extension of acute GVHD (progressive onset CGVHD), after 
a disease-free interval (quiescent CGVHD), or without pre-
ceding acute GVHD (de novo CGVHD) [21]. In patients 
with CGVHD, the skin can exhibit erythema with macules 
and plaques, desquamation, dyspigmentation, lichen planus, 
atrophy, and in severe cases, chronic ulcers. Chronic choles-
tatic liver disease can develop, as can involvement of the 
gastrointestinal tract, which may result in weight loss and 
malnutrition. CGVHD commonly produces sicca syndrome, 
which is caused by lymphocytic destruction of exocrine 
glands, most frequently affecting the eyes and mouth. The 
pathologic findings of CGVHD in the immune system include 
involution of thymic epithelium, lymphocyte depletion, and 
absence of secondary germinal centers in lymph nodes [22]. 
The skin pathology shows epidermal atrophy, dermal fibrosis, 
and sclerosis. Gastrointestinal lesions include inflammation 
and rarely, stenosis and stricture formation, particularly in 
the esophagus. Positive histological findings in the liver are 
often intensified versions of acute GVHD and include chronic 
changes, such as fibrosis, the hyalinization of portal triads, 
and bile duct obliteration. The glands of the skin and digestive 
tract show destruction of centrally draining ducts and secon-
dary involvement of alveolar components. Pulmonary tissue 
can also be involved, although histological distinctions from 
bacterial and viral infections are sometimes difficult. Never-
theless, bronchiolitis obliterans, similar to that observed dur-
ing lung transplant rejection, is now generally considered 
a manifestation of CGVHD.
IMPORTANT CHANGES IN CLINICAL 
CONSIDERATIONS
It is apparent that the clinical and histological changes 
considered characteristic of CGVHD can develop as early 
as 40 or 50 days post-transplant and thus, overlap with those 
of acute GVHD. Hence, the time of onset is increasingly 
becoming an arbitrary criterion, and it has become more 
meaningful to define the disease on the basis of clinical, 
histological, and immunologic findings.
The National Institutes of Health (NIH) have proposed 
new consensus criteria for the diagnosis and clinical assess-
ment of CGVHD, which emphasize the manifestations of 
GVHD and not time of onset after allo-HSCT (day 100) 
[23]. This proposal involves 2 categories for GVHD (acute 
or chronic), each with 2 subcategories (classic acute and 
late acute or classic chronic and overlap syndrome). In addi-
tion, a new scoring system is proposed to describe the extent 
and severity of CGVHD at each organ or site at any given 
time and that takes functional impact into account. The 
global composite scores produced and the numbers of organs 
or sites involved have been proposed as a means of assessing 
CGVHD severity, and it is expected that this system will 
replace the old grading system (limited versus extensive 
types). The feasibility of the NIH consensus criteria has been 
examined by us and others, and all studies have demonstrated 
the applicability of the new NIH criteria and described possi-
ble roles for the new global scoring system in the assessment 
of CGVHD severity [24-26].
PATHOPHYSIOLOGY OF CGVHD
Acute GVHD resembles a toxic, sepsis-like syndrome. Host 
antigen-presenting cells (APCs), especially dendritic cells 
(DCs), present alloantigens to incoming alloreactive cyto-
toxic T cells, and the subsequent actions of these T cells 
result in tissue damage to the epidermis, hepatic bile ducts, 
and gut epithelium. This process is amplified by cytokine 
release from damaged tissues and the ingress of lipopoly-
saccharide and other pathogen-associated molecular entities 
through damaged gut mucosa, which in turn up-regulate 
the innate immune system [27]. Not surprisingly, the immune 
mechanisms implicated in the induction and propagation 
of CGVHD differ from those of acute GVHD. However, 
the pathophysiology of CGVHD, unlike that of acute GVHD, 
remains obscure, as do its effective prevention and treatment. 
Fundamental research for the pathophysiology of CGVHD 
is required to develop more effective prophylactic and treat-
ment regimens. So far, at least 4 theories have been generated 
to explain how CGVHD develops (Fig. 1).
1. Breakage of immune tolerance to self-antigens (central tol-
erance) 
It has been suggested that immune tolerance to self-anti-
gens is disrupted in CGVHD, and that these give rise to 
the autoimmune manifestations of the disorder. One attrac-
tive hypothesis is that thymic epithelial damage caused by 
conditioning regimens and/or acute GVHD leads to dysregu-
lation of central tolerance mechanisms during the recon-
stitution of the immune system post-transplantation [28]. 
CD4
+ T cells generated de novo from donor stem cells appear 
to mediate the evolution of CGVHD from acute GVHD [29]. 
In fact, CGVHD occurs, even though it may not be preceded 
by acute GVHD. In healthy individuals, 95-99% of dou-
ble-positive CD4
+ CD8
+ immature T cells in the cortex of 
the thymus die through apoptosis, having failed to receive 
survival signals through their T cell receptors, a process 
referred to as “death by neglect.” Those cells that do bind 
with low affinity to MHC class I or class II upregulate CD8 
or CD4 respectively (positive selection) and survive. Since Korean J Hematol 2011;46:80-7.
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Fig. 1. The pathophysiology of chronic graft-versus-host disease.
self-antigens are also presented in the context of the cortical 
epithelial MHC complex, such T cells will have low self 
affinity. Furthermore, in the thymic medulla, single-positive 
T cells will encounter marrow-derived APCs also bearing 
self-antigens (sequestered from the blood) and if strongly 
autoreactive, will die by apoptosis (negative selection). 
Through these processes, low-affinity, self-reacting naïve 
T cells will enter the periphery, and when they encounter 
the same self-antigen/MHC complex, will receive survival 
but not activation signals. This balance between negative 
and positive selections may be lost in a pro-inflammatory 
environment and high tissue-specific autoantigen load. In 
this inflammatory environment, peripheral tolerance mecha-
nisms would be critical for regulating GVHD.
In the setting of CGVHD, central tolerance failure could 
lead to an immune disease state resembling autoimmune 
disease. Although strategies based on the administration of 
keratinocyte growth factor at the time of transplant to pre-
vent injury or repair thymic epithelium have been successful 
i n  e x p e r i m e n t a l  m o d e l s  [ 3 0 ] ,  t h e y  f a i l e d  i n  c l i n i c a l  t r i a l s  
[31]. Zhang found that host thymus is not required for the 
induction of CGVHD and that quiescent autoreactive T and 
B cells in transplants from non-autoimmune donors might 
be activated and expanded to cause CGVHD [32]. In addition, 
Imado found that transfection of the hepatocyte growth fac-
tor (HGF) gene in vivo prevented the development of CGVHD 
in a murine model [33]. HGF also protected against thymic 
injury caused by acute GVHD and thus, prevented the gen-




+ regulatory T cells (Tregs) and their relation-
ship to CGVHD




+ staining) have been reported 
to be diminished in CGVHD [34-36], although data reported 
on Treg numbers and the occurrence of CGVHD are con-
tradictory. Clark found that CGVHD is associated with ele-
vated numbers of peripheral blood Tregs and that these num-
bers returned to normal in patients with resolved CGVHD, 
thus indicating that CGVHD injury is not the result of Treg 
deficiency [37]. The mechanism by which Tregs suppress 
CGVHD remains uncertain, but there is evidence that sup-
pression is mediated by cytokines, such as transforming Korean J Hematol 2011;46:80-7.
Pathogenesis of chronic GVHD 83
growth factor (TGF)-β and interleukin (IL)-10, or by contact 
with plasmacytoid DCs through indoleamine 2,3-dioxyge-
nase [38]. Tregs may also exert an inhibitory influence di-
rectly in target tissues [39]. For example, mucosal Treg num-
bers have been documented to be lower in patients with 
GVHD than in normal controls or patients without GVHD 
[34]. Interestingly, extracorporeal photochemotherapy in-
creases levels of circulating functional Tregs in CGVHD pa-
tients [40], and recently, a novel photodepleting approach 
was found to both preserve and expand Treg numbers while 
selectively eliminating CD4
+ effector T cells from patients 
with CGVHD [41].
The adoptive transfer of Tregs in animal models of GVHD 
has demonstrated their efficacy, which suggests that Tregs 
can be exploited in the clinical setting [42]. Giorgini con-
cluded that alloantigen-driven expansion, rather than ho-
meostatic proliferation, is critical for the effectiveness of 
Tregs in CGVHD, and suggested that cellular therapy with 
alloantigen-induced Tregs in combination with glucocorti-
coids could prevent CGVHD after immune reconstitution 
[43]. Zhang, using a murine study, suggested that peripheral 
tolerance may be more critical and abrogated by donor Tregs 
[32], and Chen associated the absence of Treg control of 
T helper (Th) 1 and Th17 cells with an autoimmune-mediated 
pathology in CGVHD [44]. 
3. The roles of B cells and the antibodies they produce
Historically, research into the prevention and treatment 
of GVHD centered on donor T lymphocytes and strategies 
designed to suppress or deplete these cells. The roles of 
B lymphocytes in the pathogenesis of GVHD were high-
lighted by a case report of a patient with CGVHD who 
responded to B cell depletion therapy based on rituximab 
[45]. Considerable laboratory evidence has since revealed 
complex interactions between B and T cells that culminate 
in CGVHD. There are numerous examples of autoantibody 
formation in patients with CGVHD, but the role of autoanti-
body formation in its pathogenesis has not been elucidated 
[46]. One study, in which antibodies to platelet-derived 
growth factor (PDGF) were observed in patients with 
CGVHD but not in those without CGVHD, was of particular 
note [47]. These antibodies were found to have the capacity 
to induce both tyrosine phosphorylation of the PDGF re-
ceptor and type I collagen gene expression in fibroblasts. 
The role of B cell activity in CGVHD is underscored by 
the observation of high plasma levels of B cell activating 
factor (BAFF), a cytokine that appears to drive B cell auto-
immunity, in patients with CGVHD [48]. In fact, high plasma 
levels of BAFF at 6 months post-transplantation were found 
to predict the subsequent development of CGVHD in asymp-
tomatic patients. The development of antibodies to minor 
histocompatibility antigens (mHA) encoded on the Y chro-
mosome in male patients receiving female grafts has been 
strongly associated with CGVHD incidence [49]. Since this 
was originally observed [45], several clinical trials and case 
series have been conducted on the use of B cell depletion 
using rituximab to treat CGVHD. The evidence obtained 
supports the roles of B cells and antibodies in CGVHD and 
prompted trials of rituximab. In phase 2 trials, responses 
were documented in over 50% of subjects [50]. Recently, 
Korean researchers performed a definitive trial in an attempt 
to establish the efficacy of rituximab and concluded that 
B cells represent a promising target for the prevention and 
treatment of CGVHD [51]. Although studies on B cell deple-
tion in CGVHD have demonstrated the clinical effectiveness 
of this strategy, the mechanisms underlying the exact role 
of B cells on CGVHD are not entirely clear. In a murine 
study on the topic, it was suggested that donor B cell depletion 
protected mice from CGVHD [32], and therefore, it is con-
ceivable that alloreactive donor CD4
+ T cells could be acti-
vated by host B cells, and that this, in turn, promotes the 
activation and expansion of quiescent autoreactive donor 
B cells in stem cell grafts. Furthermore, these autoreactive 
B cells could have a central role in amplification of auto-
immune responses and in the epitope spreading of autor-
eactive T and B cells [52]. Another model of lupus CGVHD 
showed that the cytotoxic T lymphocyte (CTL)- promoting 
properties of CD40 stimulation outweigh CD4
+ T cell-driven 
B cell hyperactivity [53]. 
4. Fibrotic changes
In the skin, the initial phase of CGVHD is characterized 
by an intense mononuclear inflammatory infiltrate and de-
structive changes at the dermal-epidermal junction, accom-
panied by irregular acanthosis, hyperkeratosis, atrophy, pro-
gressing to dermal fibrosis and sclerosis [54]. Other hallmarks 
of CGVHD include the destruction of tubuloalveolar glands, 
ducts in the skin, salivary and lacrimal glands, respiratory 
epithelium, and bile ducts. A large number of experimental 
models have indicated an association between type 2 polar-
ized immune responses and the development of fibrosis [55]. 
In particular, donor type 2 immune responses were found 
to be required for the induction of cutaneous GVHD in 
mice [56]. Furthermore, Hillebrandt found that complement 
factor 5 (C5) dose-dependently modified liver fibrosis in 
mice and humans [57]. C5b-9 complexes are deposited in 
the skin, liver, lung, and kidney in mice with GVHD [58]. 
C3 is deposited at the dermal-epidermal junction in humans 
with CGVHD [59], but deposition of C5b-9 complexes has 
not been described in man. One study found that serum 
levels of TGF-β were higher in patients with CGVHD than 
in patients without CGVHD [60]. The interpretation of this 
result is complicated because assays were carried out with 
serum and not plasma, and serum contains large amounts 
of TGF-β released by platelets during clotting. Gene ex-
pression studies have demonstrated that increased TGF-β 
signaling in CD4 cells and CD8 cells is associated with a 
reduced risk of CGVHD in man [61]. The association between 
increased TGF-β activity and a reduced risk of CGVHD might 
result from a lower risk of acute GVHD, since acute GVHD 
is a well-recognized risk factor of CGVHD. Furthermore, 
skin fibrosis and the upregulation of TGF-β1 and collagen 
mRNAs commonly occur in human scleroderma and murine 
sclerodermatous GVHD following transplantation of B10.D2 Korean J Hematol 2011;46:80-7.
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lymphoid cells into irradiated BALB/c recipients [62].
There is now considerable evidence that the preferential 
expansion of Th2 cells after allo-HSCT is associated with 
the development of CGVHD in both murine models and 
humans [63-68]. As is shown by most experimental models 
of fibrosis, CD4
+ T cells play an important role in the pro-
gression of CGVHD, and the type of CD4
+ T-cell response 
that develops is crucial. Studies using various cytokine-defi-
cient mice have shown that fibrogenesis is strongly linked 
with the development of a Th2 CD4
+ T-cell response and 
that this involves IL-4, IL-5, and IL-13 [69]. Although an 
equally potent inflammatory response develops when Th1 
CD4
+ T cells, which produce interferon (IFN)-γ, dominate 
[70], under these circumstances, the development of tissue 
fibrosis is almost completely attenuated. These studies show 
that chronic inflammation does not always induce the deposi-
tion of connective-tissue elements and that the magnitude 
of fibrosis is tightly regulated by the phenotype of the devel-
oping Th-cell response. Furthermore, IL-13 and IL-4 bind 
to the same signaling receptor (IL-4Rα-IL-13Rα1) on fibro-
blasts [71]. Indeed, studies carried out using several fibroblast 
subtypes have demonstrated the potent collagen-inducing 
activities of IL-4 and IL-13 [72-74]. In addition, when the 
productions of IL-4 and IL-13 from fibroblasts are compared, 
the concentration of IL-13 often exceeds that of IL-4 by 
a factor of 10-100. This suggests that IL-13 uses a signaling 
pathway that is different in some way from that used by 
IL-4, which could provide a means of augmenting its fibro-
genic potential. In contrast to IL-13, the extent to which 
IL-5 and eosinophils participate in fibrotic processes varies 
greatly, and no clear explanation has been proposed that 
adequately explains the widely divergent findings. However, 
Jacobsohn found that monitoring the peripheral eosinophil 
count post-transplantation might provide a means of detect-
ing the development of CGVHD [75]. 
Chemokines are potent leukocyte chemoattractants that 
cooperate with pro-fibrotic cytokines such as IL-13 and 
TGF-β during the development of fibrosis by recruiting mac-
rophages and other effector cells to sites of tissue damage. 
Chemokines and their receptors have been implicated in 
the pathogenesis of scleroderma by recruiting immune cells 
to target tissues and thus, contribute to tissue damage [76]. 
Although numerous chemokine signaling pathways are prob-
ably involved in fibrogenesis, the CC-chemokine family has 
been shown to play an important regulatory role. In partic-
ular, CCL3 (macrophage inflammatory protein 1α, MIP-1α) 
and CCL2 (monocyte chemoattractant protein 1, MCP-1) 
are chemotactic for mononuclear phagocytes and have been 
identified to be essential pro-fibrotic mediators. In a murine 
CGVHD model, high levels of chemokine mRNAs, i.e., 
MCP-1, CCL5 (RANTES), CCL17, and IFN-γ-inducible che-
mokines (CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC), 
which are all monocyte/macrophage- and T cell-related, 
were observed from days 7 to 120 post-transplantation [77]. 
In a previous study, we found that pravastatin attenuates 
murine CGVHD by blocking the influx of effector cells into 
target organs and by downregulating the protein expressions 
of MCP-1 and RANTES, thereby reducing collagen synthesis 
[78]. 
CGVHD ANIMAL MODELS
Several murine allo-HSCT models have been used to study 
the pathogenesis of CGVHD. The first type of model involves 
the transplantation of parental lymphocytes into non-irradi-
ated MHC-mismatched F1 recipients [79, 80]. In this model 
type, F1 recipients develop high levels of serum anti-double- 
strand DNA (dsDNA) and glomerulonephritis, and autoanti-
body production is the result of a cognate interaction between 
donor CD4
+ T cells and host B cells [79, 81-83]. However, 
it is not clear whether mechanisms revealed by this model 
reflect the pathogenesis of CGVHD in human transplant 
recipients receiving conditioning.
The second type of model involves the transplantation 
of donor lymphocytes into MHC-matched but mHA-mis-
matched irradiated recipients. In this model, donor LP/J 
(H-2
b) bone marrow and spleen cells were transplanted into 
lethally irradiated C57BL/6 (H-2
b) recipients, which later 
developed acute and chronic forms of GVHD [84]. Clonal 
analysis of T cells from the C57BL/6 recipients indicated 
that acute GVHD development was due primarily to recipi-
ent-specific donor CTL, whereas CGVHD development was 
caused by autoreactive CD4
+ T lymphocytes [84]. 
In another mHA-disparate model, B10D2 (H-2
d) donor 
spleen cells were transplanted into lethally irradiated BALB/c 
recipients, which then developed sclerodermatous organ 
damage [32, 85]. Skin changes in this model include a mono-
nuclear infiltrate deep in dermis, loss of dermal fat, increased 
collagen deposition, and “dropout” of dermal appendages, 
s u c h  a s  h a i r  f o l l i c l e s ;  u n l i k e  t h a t  f o u n d  i n  a c u t e  G V H D ,  
the apoptosis of basal epithelial cells at the dermal-epidermal 
junction does not occur. Clinical manifestations begin as 
early as day 11 post-transplantation, and cutaneous fibrosis 
is apparent as early as day 21. Deposits of IgG, IgA, and 
IgM appear at the dermal epidermal junction in recipients 
[85]. Additional features of CGVHD in this model include 
inflammation and fibrosis in salivary and lacrimal glands, 
sclerosing cholangitis, progressive renal and gastrointestinal 
fibrosis, and the development of anti-Scl-70 antibody [86]. 
Naïve donor CD4 cells initiate the disease in this strain 
combination [87], and the derma l  i n f i l t r a t e  i s  c o m p r i s e d  
of T cells, monocytes, and macrophages [88]. T cells and 
macrophages in skin express TGF-β1 but not TGF-β2 or 
TGF-β3 mRNA [89]. In a microarray analysis study, the 
expression of type 1 (IFN-γ) and type 2 (IL-6, IL-10, and 
IL-13) cytokines, chemokines, and a variety of growth factors 
and cell adhesion molecules were upregulated in recipients 
with CGVHD compared to recipients without it [77]. 
Zhang developed a new type of CGVHD model based 
on the transplantation of DBA/2 (H-2
d) spleen cells into 
MHC-matched but mHA-mismatched, sub-lethally irradi-
ated BALB/c (H-2
d) recipients; in this model, both donor 
CD25
-CD4
+ T cells and B cells were required for CGVHD Korean J Hematol 2011;46:80-7.
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development [32]. However, the relevance of this model 
for human CGVHD is questionable because even though 
dsDNA-specific autoantibodies, immune complex glomer-
ulonephritis, and proteinuria are characteristic of systemic 
lupus, they rarely occur in patients with CGVHD [90].
CONCLUSION
Alloreactivity forms the basis of the pathogenesis of 
CGVHD, but the phenotypes and origins of the alloreactive 
cells involved remain somewhat ambiguous. Attempts to 
study CGVHD experimentally have been somewhat ham-
pered by the absence of a reliable animal model that exactly 
represents variable manifestations in humans. Nevertheless, 
thymic dysfunction, Treg deficiency, autoantibody formation 
with B cell activation, and dysregulatory fibrotic processes 
have been shown to be associated with the occurrence of 
CGVHD. Fundamental research on the pathophysiology of 
CGVHD is required for the development of more effective 
prophylactic and treatment regimens. Finally, improved 
methods of diagnosis and staging based on an understanding 
of the pathogenesis of CGVHD should help to exploit novel 
therapeutic approaches in the future.
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